Radiology.
Urology, and.
Invest Radiol. 2018 Oct;53(10):609-615. doi: 10.1097/RLI.0000000000000466.
This study investigates whether administration of low doses of gadolinium-based contrast agent (GBCA) for dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) can be as effective as a standard dose in distinguishing prostate cancer (PCa) from benign tissue. In addition, we evaluated the combination of kinetic parameters from the low- and high-dose injection as a new diagnostic marker.
Patients (n = 17) with histologically confirmed PCa underwent preoperative 3 T MRI. Dynamic contrast-enhanced MRI images were acquired at 8.3-second temporal resolution with a low dose (0.015 mmol/kg) and close to the standard dose (0.085 mmol/kg) of gadobentate dimeglumine bolus injections. Low-dose images were acquired for 3.5 minutes, followed by a 5-minute gap before acquiring standard dose images for 8.3 minutes. The data were analyzed qualitatively to investigate whether lesions could be detected based on early focal enhancement and quantitatively by fitting signal intensity as a function of time with an empirical mathematical model to obtain a maximum enhancement projection (MEP) and signal enhancement rate (α).
Both low- and standard-dose DCE-MRI showed similar sensitivity (13/26 = 50%) and lesion conspicuity score (4.0 ± 1.0 vs 4.2 ± 0.9; P = 0.317) for PCa diagnosis on qualitative analysis. Prostate cancer showed significantly increased α compared with benign tissue for low (9.98 ± 5.84 vs 5.12 ± 2.95 s) but not for standard (4.27 ± 2.20 vs 3.35 ± 1.48 s) dose. The ratio of low-dose α to standard-dose α was significantly greater (P = 0.02) for PCa (2.8 ± 2.3) than for normal prostate (1.6 ± 0.9), suggesting changes in water exchange and T2* effects associated with cancer. In addition, decreases in the percentage change in T1 relaxation rate as a function of increasing contrast media concentration (ie, the "saturation effect") can also contribute to the observed differences in high-dose and low-dose α. Area under the receiver operating characteristic curve for differentiating PCa from benign tissue using α was higher for low dose (0.769) compared with standard dose (0.625). There were no significant differences between MEP calculated for PCa and normal tissue at the low and standard doses. Moderate significant Pearson correlation for DCE parameters, MEP (r = 0.53) and α (r = 0.58), was found between low and standard doses of GBCA.
These preliminary results suggest that DCE-MRI with a low GBCA dose distinguishes PCa from benign prostate tissue more effectively than does the standard GBCA dose, based on signal enhancement rate. Diagnostic accuracy is similar on qualitative assessment. Prostate cancer diagnosis may be feasible with DCE-MRI with low-dose GBCA. In addition, comparison of enhancement kinetics after low and high doses of contrast media may provide diagnostically useful information.
本研究旨在探讨低剂量钆基对比剂(GBCA)在动态对比增强(DCE)磁共振成像(MRI)中的应用是否与标准剂量一样有效,用于区分前列腺癌(PCa)与良性组织。此外,我们评估了低剂量和高剂量注射的动力学参数的组合作为一种新的诊断标志物。
17 例经组织学证实为 PCa 的患者接受了术前 3T MRI 检查。使用低剂量(0.015mmol/kg)和接近标准剂量(0.085mmol/kg)的钆喷替酸葡甲胺团注,以 8.3 秒的时间分辨率采集动态对比增强 MRI 图像。低剂量图像采集持续 3.5 分钟,然后在采集标准剂量图像(持续 8.3 分钟)前有 5 分钟的间隔。对数据进行定性分析,以调查是否可以根据早期局灶性增强来检测病变;并通过拟合信号强度随时间的函数来进行定量分析,使用经验数学模型获得最大增强投影(MEP)和信号增强率(α)。
低剂量和标准剂量 DCE-MRI 均显示出相似的敏感性(13/26=50%)和病变显著性评分(4.0±1.0 与 4.2±0.9;P=0.317),用于 PCa 的定性分析诊断。与良性组织相比,前列腺癌的α值显著升高(低剂量为 9.98±5.84s,标准剂量为 4.27±2.20s),但低剂量和标准剂量的α值均无显著差异(P=0.317)。低剂量与标准剂量α的比值(2.8±2.3)在前列腺癌中明显大于(P=0.02)正常前列腺(1.6±0.9),提示与癌症相关的水交换和 T2*效应的变化。此外,随着对比剂浓度的增加,T1 弛豫率的百分比变化(即“饱和效应”)的降低也可能导致高剂量和低剂量α之间的观察到的差异。使用α区分 PCa 和良性组织的受试者工作特征曲线下面积(AUC),低剂量(0.769)高于标准剂量(0.625)。在低剂量和标准剂量下,计算出的 PCa 和正常组织的 MEP 没有显著差异。低剂量和标准剂量 GBCA 之间的 DCE 参数,即 MEP(r=0.53)和α(r=0.58),存在中度显著的皮尔逊相关。
这些初步结果表明,基于信号增强率,低剂量 GBCA 的 DCE-MRI 比标准剂量 GBCA 更有效地将 PCa 与良性前列腺组织区分开来,诊断准确性在定性评估中相似。低剂量 GBCA 的 DCE-MRI 可能可用于前列腺癌的诊断。此外,比较低剂量和高剂量造影剂后的增强动力学可能提供有诊断价值的信息。